In spite of effective antibiotics to treat TB (tuberculosis) since the early 1960s, we enter the new millennium with TB currently the leading cause of death from a single infectious agent, killing more than 3 million people worldwide each year. Thus an understanding of drug-resistance mechanisms, the immunobiology of cell wall components to elucidate host-pathogen interactions and the discovery of new drug targets are now required for the treatment of TB. Above the plasma membrane is a classical chemotype IV peptidoglycan to which is attached the macromolecular structure, mycolylarabinogalactan via a unique diglycosylphosphoryl bridge. The present review discusses the assembly of the mAGP (mycolylarabinogalactan-peptidoglycan) complex and the site of action
Introduction
Despite the development of the BCG (Bacille CalmetteGuérin) vaccine and chemotherapeutic agents against TB (tuberculosis) [1] , the disease remains a global health priority. The causative organism, Mycobacterium tuberculosis, is a tremendously successful colonizer of the human host and is estimated to have latently infected approx. one-third of humanity. The most recent values suggest that 8.9 million new cases of TB and 1.7 million deaths were reported worldwide in 2004 [2] . TB remains a disease firmly associated with poverty and under-developed healthcare infrastructure [3, 4] , with approx. 95 % of global TB and 98 % of TBassociated mortality borne by countries of the developing world. In developed countries, TB notifications increased alarmingly towards the end of the last century, driven by increasing globalization and immigration. The global incidence of TB rises by approx. 1 % annually, with much of this increase concentrated in sub-Saharan Africa with the major exacerbating factor being HIV [2, 5] . The retroviral infection renders individual sufferers more susceptible to infection and reactivation of LTBI (latent TB infection). The estimated annual risk of re-activation among those coinfected with HIV and TB is approx. 5-8 % compared with a cumulative lifetime risk of 5-10 % in HIV-negative adults.
Infection with M. tuberculosis does not necessarily transform into active disease. Only 20-50 % of individuals that are exposed to M. tuberculosis become infected, and approx. 5 % of these develop pulmonary disease or some clinical form of TB over 2-5 years. The other 95 % of infected individuals develop LTBI. Active pulmonary TB is highly contagious and the prevention of the transition from latent to active pulmonary TB is nearly impossible. Reactivation of the pathogen occurs as a consequence of deficiency in the immune system and leads to disease. Individuals with LTBI have an approx. 5 % lifetime chance of reactivating their latent infection, resulting in the development of clinical TB.
In 2004, the country with the highest incidence of TB was South Africa, with 718 cases per 100 000 people. India has the largest number of infections, with over 1.8 million cases [6] . In developed countries, TB is less common and is mainly an urban disease. In the U.K. in 2004, there were 344 reported TB-related deaths, and the national average of mortality was 0.65 per 100 000. The highest rates in Western Europe are in Portugal (42 per 100 000) and Spain (20 per 100 000). These rates compare with 113 per 100 000 in China and 64 per 100 000 in Brazil. In the U.S.A., the overall TB case rate was 4.9 per 100 000 persons in 2004 (http://www.cdc.gov). The incidence of TB varies with age. In Africa, TB primarily affects adolescents and young adults [6] . However, in countries where TB has gone from high to low incidence, such as the U.S.A., TB is mainly a disease of the elderly.
Historical perspective of anti-TB chemotherapy
The 'golden age' of TB chemotherapy (reviewed in [7] ) began with the discovery of the aminoglycoside streptomycin by Waksman and colleagues in 1944 [1] . The potent antitubercular activity of PAS (p-aminosalicylic acid) was first discovered in 1957. In 1952, the investigation of nicotinamide activity on M. tuberculosis in vivo led to the simultaneous discovery of INH (isoniazid) and PZA (pyrazinamide). Further development of the same lead gave rise to ETH (ethionamide) and PTH (prothionamide). In 1961, investigation of the anti-TB activity of polyamines and diamines prompted the production of a series of diamine analogues that gave rise to EMB (ethambutol). Several other anti-TB agents were discovered from the screening of compounds produced by soil organisms, including cycloserine, kanamycin, viomycin, capreomycin, rifamycin and its derivative RIF (rifampicin). Using this array of agents, modern TB therapy was developed, with the only significant introduction to the anti-TB arsenal since the 1960s being the introduction of the broad-range quinolones to TB therapy in the late 1980s.
Currently the recommended standard chemotherapeutic regimen for TB treatment is prescribed under DOTS (directly observed treatment, short-course). Initially, the acronym described the chemotherapy regimen, but has latterly become the term used to describe a broader public health strategy with five principal elements: (i) political commitment; (ii) case detection by sputum smear microscopy; (iii) standard shortcourse chemotherapy with supportive patient management, including DOTS; (iv) a system to ensure regular drug supplies; and (v) a standard recording and reporting system, including the evaluation of treatment outcomes [8] . The chemotherapeutic regimen consists of an initial two-month phase of treatment with INH, RIF, PZA and EMB, followed by a continuation phase of treatment lasting 4 months with INH and RIF.
INH and RIF represent the cornerstones of anti-TB therapy; INH is the most powerful mycobactericidal drug available, normally ensuring early sputum conversion and consequently decreasing the transmission of TB. RIF, by its mycobactericidal and sterilizing activities is crucial for preventing relapses. Strains of M. tuberculosis resistant to both INH and RIF, regardless of profiles of sensitivity/ resistance to other drugs, have been termed MDR (multidrugresistant) strains. MDR-TB is a major concern as TB patients that fail to respond to treatment have a high risk of death. Although resistance to either drug may be managed with other first-line drugs, MDR-TB requires treatment with secondline drugs under DOTS-Plus. These drugs possess limited sterilizing capacity and are not suitable for short-course treatment, necessitating prolonged treatment with drugs that are less effective and more toxic. Recently, the emergence of XDR (extensively drug-resistant)-TB strains with resistance to at least three of the six classes of second-line drugs (aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine and PAS) have been reported. In some regions, almost 20 % of MDR-TB cases were classified as XDR-TB, raising concerns over a future epidemic of virtually untreatable TB [9] . Given this backdrop, the need for rapid and continued progress in the development of new antimicrobials active against M. tuberculosis is a high priority. Importantly, enhanced penetration of infection sites, such as lung cavities, and long biological half-lives, might represent advances towards shortening therapy and lead to simpler treatment regimens with improved patient compliance.
The need for new drugs that target the cell wall of TB
It is felt that adding new drugs that act on actively growing tuberculosis organisms will only help with treating MDR organisms (admittedly an increasing problem), but may do little to tackle the main problem, which is the length of time of treatment. For this, drugs that kill non-multiplying persistent organisms are needed. Historically, inhibitors of cell wall synthesis since their discovery in the 1950s have been the mainstay of many chemotherapeutic regimens. Agents such as INH, an inhibitor of mycolic acid biosynthesis, when implemented into DOTS has proved highly successful in combating 'drug-sensitive' TB. However, a key issue is the spread of MDR-TB. As a result, the search for new drug targets and cheap alternative agents is greatly needed, which represents a central theme in TB drug development. Although drugs that act on non-replicating forms appear desirable on theoretical grounds, there is no direct evidence that their use would actually accelerate TB therapy. It is impossible to know how new drugs will have an impact on time to cure and we need to await animal and clinical trial data before drawing any such conclusions. Also, the challenge of drug resistance and adverse drug reactions means that, in a significant number of cases, cheap effective alternative agents are being explored. As a result, there will always be a place for new drugs in these areas, with cell wall inhibitors being highly profitable in the past.
The mycobacterial cell wall
There is an unusually high content of lipids in mycobacteria, comprising approx. 60 % of the dry weight, much higher than other Gram-positive (0.5 %) and Gram-negative (3 %) bacteria. The cell envelopes of mycobacteria exhibit lowpermeability due to the high proportion of lipids and associated complex lipids. These are organized as a physical barrier to a variety of agents. This permeability barrier is thought to play a crucial role in the intrinsic resistance of M. tuberculosis to antibiotics, chemical injury and lytic enzymes. The first model of the mycobacterial cell wall incorporating an outer lipid bilayer, was proposed by Minnikin [10] . This model has been modified by McNeil and Brennan [11] to incorporate complex lipids and novel insights into PG (peptidoglycan) organization.
In all of these models, the cell-bound mycolic acid residues, which form the inner leaflet of the outer membrane, are esterified to a branched arabinofuranose motif [12] . This motif decorates the non-reducing end of a linear arabinan chain, which is, in turn, linked to a linear galactan chain, together known as AG (arabinogalactan) [13, 14] . This whole assembly is attached to the glycan moiety of the PG via a unique RhaGlcNAc-phosphate (where Rha is rhamnose) linker [15] . This covalently linked structure is known as the mAGP (mycolyl-arabinogalactan-peptidoglycan) complex, which has been the subject of much study in recent years.
The PG layer consists of a highly cross-linked polymer of amino acids and amino sugars. The glycans are thought to be arranged in a grid-like array perpendicular to the plane of the plasma membrane and cross-linked by stem peptides. Earlier models depicting the structural organization of the mycobacterial cell wall assume that PG and galactan strands run in parallel to the cytoplasmic membrane, forming several horizontal layers beneath the perpendicularly oriented mycolic acids. Dmitriev et al. [16] re-evaluated the current chemical, biochemical and electron microscopical data and proposed a fundamentally distinct principle of the physical organization and biosynthesis of the mycobacterial cell wall skeleton. According to this new concept, the cross-linked glycan strands which all run perpendicular to the plane of the cytoplasmic membrane are found in a coiled conformation. The organization of stem-peptide cross-linking during logarithmicphase growth is DAP (meso-diaminopimelate) linked to D-alanine and, during stationary-phase growth, the link is in a DAP→DAP conformation, the latter being associated with penicillin resistance. In addition, the coiled galactan domains of mAGP intercalate with the coiled glycan domains of PG between the stem-peptide cross-links, the chains being linked by the Rha-GlcNAc-phosphate linker unit [15] . An assortment of surface glycolipids complement the mAGP complex to provide an outer lipid bilayer; this configuration, as mentioned above, has been speculated to provide a protective barrier to drug permeation.
LU (linker unit) and AG structure
The LU of AG is believed to be the Achilles heel of the complex, since the whole mAGP is attached to PG via this unique unit. The galactan region of AG is linked to the C-6 of some of the MurNGly (N-glycolylmuramic acid) residues via the LU. The LU consists of a diglycosyl-P bridge,
α-L-Rhap-(1→3)-α-D-GlcNAc-(1→P).
Recent studies using gas chromatography-MS and fast-atom bombardment MS established that: (i) the arabinose (Ara) and galactose (Gal) residues are both in the furanose (f ) ring form; (ii) the galactan region of AG is linked to the C-6 of some of the MurNGly residues of PG via a special diglycosyl-P bridge, α-L-Rhap-(1→3)-D-GlcNAc-(1→P); (iii) the galactan region consists of a linear alternating 5-and 6-linked β-D-Galf (galactofuranose) residues; (iv) the arabinan chains are attached to C-5 of some of the 6-linked Galf residues, and two or three arabinan chains are attached to each galactan strand; (iv) the arabinan chains are mostly composed of α-5-linked α-D-Araf (arabinofuranose) residues with branching introduced at 3,5-α-D-Araf residues; (v) the non-reducing termini of arabinan consists of a hexasaccharide motif
and (vi) the mycolic acids are located in clusters of four on the terminal hexa-arabinofuranoside, with only two-thirds of these being mycolated.
LU and AG biosynthesis
LU assembly is dependent on the transfer of GlcNAc-1-phosphate from UDP-GlcNAc to the lipid carrier decaprenyl monophosphate catalysed by rfe [17] (Figure 1 ). The L-rhamnosyl component is provided by a sugar donor, dTDPrhamnose, from a four-step reaction. The four enzymes, α-D-glucose-1-phosphate thymidylyltransferase (RmlA), dTDP-D-glucose-4,6-dehydratase (RmlB), dTDP-4-oxo-6-deoxyglucose-3,5-epimerase (RmlC) and dTDP-6-deoxy-Llyxo-4-hexulose reductase (RmlD) catalyse the conversion of α-D-glucose-1-phosphate and TTP into dTDP-rhamnose. The inactivation of rmlD in Mycobacterium smegmatis [18] , and more recent knockout mutant studies in M. smegmatis, confirmed that rmlB, rmlC and rmlD are essential for mycobacterial growth [18, 19] . Hence, dTDP-Rha is an essential component for mycobacterial growth and enzymes involved in its synthesis are potential chemotherapeutic targets. In Escherichia coli, wbbL has been identified as the rhammosyltransferase involved in lipopolysaccharide biosynthesis. Similarly, Rv3265c [KEGG (Kyoto Encyclopedia of Genes and Genomes) accession number] from M. tuberculosis has been shown to exhibit rhamnosyltransferase activity involved in LU biosynthesis and has been shown to be an essential enzyme [20] .
In Mycobacterium and Cornyebacterium spp., the initiation of DPA (decaprenylmonophosphoryl-D-arabinose) biosynthesis has been shown to utilize UbiA in forming DPPR (decaprenylphosphoryl-5-phosphoribose). Subsequently, the epimerization of DPPR to DPPA (decaprenylphosphoryl-5-phosphoarabinose) occurs via an epimerase mechanism involving Rv3790 and Rv3791 [21, 22] . The enzyme involved in dephosphorylation of DPPA to DPA is as yet to be elucidated in mycobacteria. The primary cellular targets of EMB were described as EmbAB in Mycobacterium avium and EmbCAB in M. tuberculosis [ 23, 24] . It was shown that they were responsible for the polymerization of arabinose into the AG complex and LAM (lipoarabinomannan). Disruption of either embA or embB in M. smegmatis resulted in the impairment of the synthesis of β-D-Araf -1→2-β-D-Araf disaccharide to the 3-position of the 3,5-linked Araf residue, resulting in a linear terminal motif [25] . Therefore EmbA and EmbB are crucial for the formation of the hexa-arabinofuranosyl motif of AG, an important structure for the esterification of mycolic acids. Recently, it was shown that the synthesis of LAM, but not AG, ceases after inactivation of embC in M. smegmatis by insertional mutagenesis [26] . Thus the Emb proteins are capable of differential recognition of the galactan or mannan acceptors before appropriate arabinosylation. The recent deletion of emb in Corynebacterium glutamicum revealed a dramatic reduction of arabinose, resulting in a novel truncated AG structure possessing only terminal Araf residues with a corresponding loss of cell wall bound mycolic acids [27] . More recently, AftA has been shown to catalyse the addition of the first key arabinofuranosyl residue from the sugar donor DPA to the galactan domain of the cell wall, thus 'priming' the galactan for further elaboration by the EMB arabinofuranosyltransferases [28] . Recently, a retaining glycosyltransferase family C enzyme was identified, now termed AftB, which is responsible for the attachment of terminal β(1→2) Araf residues, and marks the 'end point' for AG arabinan biosynthesis (Figure 1 ) before decoration with mycolic acids [29] . It is clear that additional arabinofuranosyltransferases still remain to be identified involved in AG and LAM biosynthesis.
Lipoarabinomannan
LAM and its truncated form lipomannan (LM) are thought to be the primary plasma membrane-associated lipopolysaccharides in mycobacteria. LAM is present in the envelopes of pathogenic mycobacteria, such as M. tuberculosis and Mycobacterium leprae, the vaccine strain Mycobacterium bovis BCG and opportunistic strains, such as M. avium, Mycobacterium kansasii, Mycobacterium fortuitum and Mycobacterium chelonae and, finally, the fast-growing non-pathogenic strain M. smegmatis. The biological and immunological properties of LAM are significant and have been studied extensively. Mycobacterial LAMs are lipoglycans that comprise three distinct domains: an MPI (mannosyl-phosphatidylmyo-inositol) anchor, a polysaccharide backbone and capping moieties. The anchor structure is heterogeneous, with variations in the number and location of fatty acid residues. Its acylation with a combination of palmitic, stearic and tuberculostearic (10-methyloctadecanoic) acids facilitates the interaction of the anchor and the plasma membrane.
The polysaccharide backbone is composed of two homopolysaccharides, D-mannan and D-arabinan. The structure of this backbone is highly conserved among different mycobacterial species. The mannan core is composed of approx. and →5)-Araf -(α1→5)-Araf -(α1→)}. The terminal residues of the arabinan domains are decorated with various 'caps'. Two capping motifs have been identified for LAM. Mannooligosaccharides cap the LAM of slow-growing mycobacteria, such as M. tuberculosis which have now been termed ManLAM [30] . Phosphoinositide units cap LAM from fastgrowing mycobacteria, such as M. smegmatis [31, 32] . The LAM of M. chelonae has been shown to be devoid of any caps and has been termed AraLAM [33] . ManLAM and PILAM (phospho-myo-inositol-capped LAM) exhibit a broad spectrum of immunomodulatory activities. The main immune response activities of ManLAM derive from its ability to inhibit the activation of macrophages and to inhibit the production of the Th1 pro-inflammatory cytokines IL-12 (interleukin 12) and TNFα (tumour necrosis factor α). M. tuberculosis ManLAM is also able to induce apoptosis in macrophages [34, 35] .
LAM biosynthesis
Recent studies have elucidated a number of the key steps in LAM biosynthesis ( Figure 2) ; however, our knowledge of its complete synthesis is still somewhat fragmented. The biosynthetic scheme for the biosynthesis of this membrane molecule has been proposed as PI→PIM (phosphatidyl-myoinositol mannoside)→LM→LAM. Recent studies have led to the identification of several key α-mannosyltransferease, PimA, PimB (and PimB ) and PimC. Kordulakova et al. [36] identified PimA which catalyses the transfer of a mannose residue from GDP-Man to the 2-position of PI to form PIM 1 . PIM 1 is then further glycosylated by PimB (Rv0557), which may occur before, or after acylation of PIM 1 by Rv2611c [37] and results in the formation of Ac 1 PIM 2 (mono-acylated PIM 2 ) [38] . However, recently, this second mannosylation step in the biosynthesis of Ac 1 PIM 2 has been shown to be catalysed by PimB (Rv2188c and NCgl2106) [39, 40] , whereas PimB now termed MgtA is involved in the synthesis a novel mannosylated glycolipid, 1,2-di-O-C 16 / C 18:1 -(α-D-mannopyranosyl)-(1→4)-(α-D-glucopyranosyluronic acid)-(1→3)-glycerol (ManGlcAGroAc 2 ) and a hypermannosylated variant [41] . Previous studies have shown that RvD2-ORF1 from M. tuberculosis CDC1551, designated as PimC, catalysed further mannosylation of Ac 1 PIM 2 , resulting in Ac 1 PIM 3 [42] . Further elaboration of this pathway has revealed the presence of a redundant pathway from mono-acylated PIM 4 , by the addition of Manp residues from the alkali-stable sugar donor C 50 /C 35 -PPM (polyprenol monophosphomannose) [43] and PimE to form α(1→2)-branched 'higher' PIMs in the form of mono-acylated PIM 5 [44, 45] . Subsequently, mono-acylated PIM 5 is then mannosylated further to mono-acylated-PIM 6 . An additional parallel biosynthetic pathway extends monoacylated PIM 4 to linear LM via a PPM-dependent α(1→6)-mannosyltransferase MptA and subsequently to a branched-LM via an α(1→2)-mannosyltransferase (Rv2181) [46, 47] . The transition of LM to LAM has recently been shown to occur exclusively by EmbC. An M. smegmatis embC mutant was found to be devoid of LAM [26] . Furthermore, AG biosynthesis was unaffected by the mutation, indicating the essentiality of EmbC towards LAM biosynthesis. Recently a novel α-mannosyltransferase, MT1671 (and Rv3265c), has been shown to add terminal Manp residues to the mature LAM in M. tuberculosis to form ManLAM [48, 49] .
Mycolic acids
Mycolic acids are high-molecular-mass (C 60 -C 90 ) α-alkyl β-hydroxy fatty acids. In M. tuberculosis, they comprise approx. 40-60 % of the dry weight of the bacterium. As well as being found esterified to AG, mycolic acids are also present in lipids that are extractable with organic solvents. These are mainly found in the form of TDM (trehalose 6,6 -dimycolate) and TMM (trehalose monomycolate) and account for 6 % of the lipid population. Mycolic acids possess at least two chiral centres at positions α and β to the carboxylic acid group. Although the basic mycolate structure is well conserved, there are a number of modifications at two mid-chain positions that identify different classes of mycolic acids in M. tuberculosis. These modifications include the incorporation of both cis-and trans-cyclopropane rings, cis and trans double bonds, oxo-, methoxy-, epoxy-and wax-ester functional groups in addition to the characteristic α-mycolic acids which contain no oxygen functionality groups at the proximal or distal positions. The polar oxygencontaining functions are found at the distal position with non-polar cyclopropane modifications found at the proximal position. Oxy-and methoxy-mycolates have also been shown to possess trans-cyclopropane and cis-cyclopropane rings. Cyclopropane rings and double bonds occurring in a trans conformation also possess an adjacent methyl group.
Mycolic acid biosynthesis
Mycolic acid biosynthesis can be divided into sequential steps: (i) de novo fatty acid biosynthesis; (ii) elongation; (iii) modification of the meromycolate; and (iv) Claisen condensation and reduction (Figure 3 ). The synthesis of fatty acids involves the extension of the growing alkyl chain by a two-carbon unit via the repetition of a four-part cycle of reactions. The first reaction in each cycle is a condensation reaction in which a malonate residue is decarboxylated and undergoes a condensation reaction with a thioester-linked fatty acyl chain. This reaction achieves the extension of the acyl chain, and the remaining three reactions involved in fatty acid biosynthesis remove the resulting β-oxo group of the product and return the chain to its aliphatic form. First, the β-oxo product is reduced to form a β-hydroxy intermediate, which is then dehydrated to form an enoyl product that is subsequently reduced. The saturated aliphatic substrate is then passed on for the next round of chain extension.
Two types of FAS (fatty acid synthase) are known, both containing similar enzymatic functions, but differing in their organization. A single gene encodes FAS-I, commonly found in mammals, and the active homodimeric protein possesses all the necessary functions to perform de novo fatty acid biosynthesis from acetyl-CoA and malonyl-CoA. Most bacteria and plants, however, utilize FAS-II in which the growing fatty acyl chain is shuttled between the active sites of disassociated enzymes as an acyl thioester of a small and highly acidic ACP (acyl carrier protein). Mycobacteria are unusual in that they contain both FAS-I and FAS-II. FAS-I encoded by fas, is responsible for de novo fatty acid biosynthesis, producing a bimodal distribution of C 16 -C 26 fatty acids, mainly thioesters of CoA. FAS-II of M. tuberculosis is similar to other bacterial FAS-II enzymes except for its primer specificity. The M. tuberculosis FAS-II extends relatively long acyl-chain thioesters of AcpM, a C-terminally extended homologue of other bacterial ACPs, to provide long-chain meromycolates, leading ultimately to mature mycolic acids.
The β-oxoacyl-ACP synthase III, mtFabH (Rv0533c), has been proposed as the pivotal link between FAS-I and FAS-II [50] . mtFabH elongates acyl-CoA primers derived from FAS-I, forming β-oxoacyl-AcpM thioester products through condensation with malonyl-AcpM. In the proposed reaction mechanism, mtFabH is initially transacylated, with the incoming acyl-CoA forming a thioester with the active-site cysteine residue (Cys 122 ), its CoA moiety being released [51] . The docking of malonyl-AcpM is followed by decarboxylation of the malonate residue. The resulting carbanion attacks the acyl-enzyme thioester linkage, thereby initiating the condensation reaction. The reduction of the characteristic β-oxo group to a hydroxy function is carried out by the β-oxoacyl-ACPreductase, MabA (Rv1483). mabA has been cloned and expressed in E. coli, and its NADPH-dependent β-oxoreductase activity has been characterized biochemically [52] . The recent crystal structure of MabA has led to the recognition of structural differences that may distinguish M. tuberculosis MabA from most of the other known β-oxoacyl-ACP reductases [53] . The genes encoding the essential dehydratase function converting the β-hydroxyacyl-AcpM product of MabA into the enoyl-AcpM substrate for InhA have recently been identified in M. tuberculosis and M. smegmatis [54, 55] . Heterodimers of Rv0635-Rv0636 and Rv0637-Rv0636 can both function in vitro as β-hydroxyacyl-AcpM dehydratases. In M. tuberculosis, mabA lies adjacent to inhA (Rv1484), which encodes an NADH-specific 2-trans-enoyl-ACP reductase involved in FAS-II. A detailed biochemical study has demonstrated that InhA prefers long-chain substrates, consistent with its involvement in long-chain fatty acid biosynthesis [56, 57] . The subsequent rounds of acyl extension in FAS-II are thought to be initiated by the highly homologous β-oxoacyl-ACP synthases, KasA (Rv2245) and KasB (Rv2246). Both enzymes have been expressed in E. coli, purified and characterized [58] [59] [60] . Both extend acyl-ACP thioesters, rather than acyl-CoA, condensing them with malonyl-ACP. Both enzymes prefer acyl-ACPs greater than 16 carbons in length, consistent with their proposed role in FAS-II biosynthesis.
In M. tuberculosis, kasA and kasB are clustered with a series of genes implicated in fatty acid biosynthesis, which presumably form an operon. These include acpM and fabD, the latter encoding a malonyl-CoA acyltransferase responsible for the formation of the malonyl-AcpM which is used as a substrate by mtFabH, KasA and KasB [61] . It has been shown that KasB is not essential in Mycobacterium marinum and M. tuberculosis, although the kasB deletion mutant grew poorly in macrophages and deletion in M. tuberculosis caused a loss of acid-fastness and subclinical latent TB in immunocompetent mice [62, 63] . Detailed chemical analysis of mycolic acids from the kasB mutant found that they were two to four carbons shorter than mycolic acids isolated from wild-type bacilli. The defect was localized to the proximal portion of the meromycolate chain. The kasB mutant also showed a significant reduction in the abundance of ketomycolates, with a slight compensatory increase in both α-and methoxymycolates. Despite these small changes in mycolate length and composition, the kasB mutants exhibited strikingly altered cell wall permeability, with increased susceptibility to lipophilic antibiotics and host antimicrobial molecules.
Meromycolate modification
Analysis of the M. tuberculosis genome identified three potential desaturases, DesA1, DesA2 and DesA3, which have been speculated to form the double bonds of mycolic acids. Cyclopropanation is a common modification in mycolic acids from slow-growing pathogenic mycobacteria, whereas fastgrowing species (e.g. M. smegmatis) do not produce cyclopropanated mycolates, but produce large amounts of unsaturated mycolic acids. The overproduction of M. tuberculosis cma1, a putative cyclopropane synthase in M. smegmatis, resulted in distal cyclopropanation of α-mycolates [64] . However, deletion of cmaA1 in M. tuberculosis did not alter α-mycolates, indicating an as-yet-unidentified role for CmaA1 [65] . Through the use of a cmaA1 gene probe, other meromycolate-modifying enzymes were identified as mma1-mma4 encoding MMAS (methyltransferase mycolic acid synthesis)-1-MMAS-4 [66] . It was subsequently shown that both the cma and mma genes have a high degree of homology and share a highly-conserved SAM binding region.
Although, the function of MMAS-1 (mmaA1) was not obvious, overexpression studies in M. tuberculosis suggested that MMAS-1 regulated a branch point between cis-and trans-cyclopropane-containing oxygenated mycolates [67] . Deletion of mmaA2, on the other hand, resulted in the loss of distal cis-cyclopropanation of α-mycolates and lower than normal levels of proximal cis-cyclopropanation of methoxymycolates [65] . The overexpression of MMAS-3 (mmaA3) in M. tuberculosis led to the total replacement of ketomycolates with methoxymycolates, resulting in numerous effects, such as increased permeability properties of the cell wall consistent with the hypersensitivity to both ampicillin and RIF, impaired growth at low temperature and the inability to replicate in macrophage THP-1 cells [68] . These results suggested that MmaA3 O-methylates the distal secondary alcohol in the formation of cis-and trans-methoxymeroacids. A strain of M. tuberculosis devoid of mma4 activity was unable to synthesize oxygenated mycolates and was unable to grow in THP-1 cells [69] . Biochemical analyses showed that MmaA4 was involved in the MmaA4 introduction of the distal-branch methyl group in the formation of trans-oxygenated meroacids.
Glickman et al. [70] demonstrated that the cmaA2 is actually required for the synthesis of trans-cyclopropane rings of both ketomycolates and methoxymycolates, defining cmaA2 as a mycolic acid proximal trans-cyclopropane synthase. Additionally, deletion of M. tuberculosis PcaA, a homologue of cmaA2, resulted in the loss of the proximal cis-cyclopropane ring in α-mycolates [71] .
Although there is no supporting experimental evidence, the co-ordination of meromycolate elongation and modification in multi-enzyme complexes seems to be a likely route to efficient meromycolate biosynthesis.
Claisen condensation and deposition of cell-wall-bound mycolic acids
Portevin et al. [72] and Gande et al. [73] were the first to identify Pks13 (polyketide synthase 13) as the enzyme complex involved in the final assembly of mycolic acids in M. tuberculosis. A specific FadD32 (fatty acyl-AMP ligase) converts each meroacyl-S-ACP derived from the FAS-II system (α-, oxo-and methoxy-meroacyl-ACP) into meroacyl-AMP. The C 26 -S-CoA derived from FAS-I (after the release from the enzyme as the CoA derivative) is carboxylated by AccD4 (Rv3799) and AccD5 (Rv3280) (acyl carboxylase) to yield the 2-carboxyl-C 26 -S-CoA. The proposed mechanism of Claisen-type condensation involves the following. (i) The binding of the C 52 -α-meroacyl chain from its AMP derivative and a 2-carboxyl-C 26 -acyl chain from its CoA derivative to the N-terminal PPB (phosphopantetheine-binding) domain and the near C-terminal PPB domain of Pks13 respectively, both as thioesters. In the former reaction, the acyltransferase (AT) enzyme is presumed to be specific for the AMP derivative.
(ii) The transfer of an α-meroacyl group from the N-terminal PPB domain to the KS (ketoacyl synthase) domain, presumably catalysed by the acyltransferase at the acyltransferase domain. (iii) The Claisen-type condensation of the two fatty acyl groups. A nucleophilic attack of the carbonyl group of the α-meroacyl-S-KS by the acidic α-carbon of the 2-carboxyl-C 26 -S-PPB results in the formation of 3-oxo-C 78 -α-mycolate bound to the near C-terminal PPB domain and the release of CO 2 and KS. The reduction step, where an oxoreductase converts the 3-oxo into the secondary alcohol to yield the mature C 78 -α-mycolate [74] . The thioesterase (TE) domain is thought to be involved in the release of the mature mycolate.
The deposition and export of mycolates to the cell wall has been partially elucidated. A mycolated polyprenyl phosphate-linked carrier described as Myc-PL (6-O-mycolyl-α-D-mannopyranosyl-1-monophosphoheptaprenol) from M. smegmatis [75] has been implicated in the final stages of mAG synthesis. The introduction of [
14 C]Myc-PL into a cell wall preparation from M. smegmatis led to the transfer of [ 14 C]mycolates into extractable TMM and TDM as well as insoluble mycolates esterified to AG [75] . Belisle et al. [76] demonstrated further that three members of the M. tuberculosis antigen 85 complex, Ag85A, Ag85B and Ag85C2 (encoded by fbpA, fbpB and fbpC2 respectively), were able to catalyse mycolyltransferase reactions, leading to mycolylation of the cell wall.
Concluding remarks
The mycolyl-arabinogalactan complex is a unique component of the M. tuberculosis cell wall. It shields the bacterium from a harsh environment inside an infected macrophage and is also responsible for lesser sensitivity to many antibiotics. Furthermore, LAM and TDM are immunomodulatory and thus play an important role in interactions of M. tuberculosis with the host cell. Additionally, mycolic acid biosynthesis is essential for mycobacterial survival. Sequencing of several mycobacterial genomes, advances in the genetic tools for mycobacteria and the use of surrogate systems such as corynebacteria have helped a great deal in the identification of enzymes that are involved in the biosynthesis of the mycolatearabinogalactan complex. Delineating the pathways to biosynthesis of these critical components of mycobacteria has thus not only helped in understanding the biology of this human pathogen, but also has set the stage for the next 
